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Abstract
Members of the ETS transcription factor family have been implicated in several cancers, where
they are often dysregulated by genomic derangement. ETS variant 1 (ETV1) is an ETS factor gene
that undergoes chromosomal translocation in prostate cancers and Ewing's sarcomas, amplification
in melanomas, and lineage dysregulation in gastrointestinal stromal tumors. Pharmacologic
perturbation of ETV1 would be appealing in these cancers; however, oncogenic transcription
factors are often deemed “undruggable” by conventional methods. Here, we used small-molecule
microarray (SMM) screens to identify and characterize drug-like compounds that modulate the
biological function of ETV1. We identified the 1,3,5-triazine small molecule BRD32048 as a top
candidate ETV1 perturbagen. BRD32048 binds ETV1 directly, modulating both ETV1-mediated
transcriptional activity and invasion of ETV1-driven cancer cells. Moreover, BRD32048 inhibits
p300-dependent acetylation of ETV1, thereby promoting its degradation. These results point to a
new avenue for pharmacological ETV1 inhibition and may inform a general means to discover
small molecule perturbagens of transcription factor oncoproteins.
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INTRODUCTION
ETV1 is an oncogenic transcription factor that lacks an enzymatic activity and therefore is
deemed “undruggable” by conventional means (1). A significant proportion of the
“undruggable” oncoproteins are transcription factors that become deregulated by various
somatic genetic events, including gene amplification or balanced translocation (2, 3). The
ETS transcription factor family includes several well-known oncogenes affected by genetic
aberrations across multiple tumor types (4). For example, 80% of Ewing's sarcomas (5)
harbor FLI1 (ETS factor) translocations and a majority of prostate cancers harbor
chromosomal translocations of the ERG (V-Ets Erythroblastosis Virus E26 Oncogene
Homolog Avian), ETV1 and ETV4 (ETS variant 4) ETS factor genes (6). In prostate cancer,
these translocations arise in the setting of chromoplexy (7) and yield fusion genes involving
androgen-regulated upstream partners such as TMPRSS2 (Transmembrane protease, serine
2) or housekeeping genes (8, 9).
ETV1 is an ETS transcription factor oncogene that is altered in several cancers.
Translocations are observed in Ewing's sarcoma and prostate cancer, amplification occurs in
melanoma (10), and oncogenic lineage dysregulation seems ubiquitous in gastrointestinal
stromal tumors (11). These genetic events induce aberrant activation of transcriptional
programs that govern various aspects of tumorigenesis (12, 13). ETV1 is phosphorylated
downstream of mitogen-activated protein kinase (MAPK) signaling (14), which enhances its
protein stability (15). In addition, the histone acetyltransferase (HAT) p300 (E1A binding
protein p300) binds and acetylates ETV1 at lysines 33 and 116 (16), with both events
leading to increased protein half-life and enhanced transcriptional activity (17, 18). A
putative “degron” sequence in the N-terminal region of ETV1 may control its COP1-
dependent, proteasome-mediated degradation (19, 20).
In recent years, several small molecules that bind and inhibit regulators of oncogenic
transcription factors have been reported. The identification of JQ-1 as a bromodomain
perturbagen is exemplary in this regard (21). Research to develop tool compounds that
interfere with oncogenic ETS factors led to the discovery of YK-4-279, which modulates
several ETS family members including ERG, ETV1, and FLI1 (22, 23). However, much
more work is needed to develop systematic approaches to identify small-molecule
“perturbagens” of oncogene transcription factors in general and ETS factors in particular.
Small molecule microarray (SMM) screening has been described as a high-throughput
means to interrogate many thousands of diverse chemical species for their ability to bind
various types of proteins (24). As such, we sought to use small-molecule microarrays
(SMMs) to identify putative ETV1-binding compounds. We reasoned that a subset of such
compounds might also inhibit its function and thereby provide new insights into
pharmacological perturbation of these and other transcription factor oncoproteins. These
efforts identified BRD32048, a compound that binds ETV1 directly in vitro and inhibits its
transcriptional activity through a mechanism that involves altered acetylation and
compound-induced ETV1 degradation. These results provide new insights into mechanisms
that suppress ETV1 activity and may provide a generalizable approach to identify chemical
probes of traditionally “undruggable” protein targets.
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METHODS
SMM screening
Each SMM slide contained approximately 10,800 printed features including 9000 unique
compounds and was prepared as described previously (25). In total 45,000 compounds were
screened. The collection contained commercially available natural products, FDA-approved
drugs, known bioactive small molecules, and products of diversity-oriented synthesis (24,
26-28). Each sample was screened against three replicate SMMs. Lysates were prepared
from HEK293T cells overexpressing HA-tagged ETV1 or vector alone as control. Cells
were lysed in MIPP lysis buffer (20 mM NaH2PO4, pH 7.2, 1 mM Na3VO4, 5 mM NaF, 25
mM β-glycerophosphate, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, 0.5% Triton X-100,
complete protease inhibitors). The concentration of total protein was adjusted to 0.3 mg/mL
where ETV1 protein was at approximately 0.5 μg/mL lysate, estimation obtained by
comparing western blot signals of lysates and known amounts of purified ETV1. Each slide
was incubated with 3 mL of adjusted lysate for 1 hour at 4 °C followed by anti-HA mouse
monoclonal (Covance) at 1:1000 for 1 hour at 4 °C in PBS-T buffer (1× phosphate buffered
saline, 0.1% Tween-20) supplemented with 0.5% (w/v) BSA. A Cy5-labeled anti-mouse
secondary antibody (Millipore) for detection was incubated at 1:1000 using the same
conditions. Each incubation step was followed by three washes in PBS-T. Finally the slides
were briefly rinsed in distilled water and spin-dried (26). The slides were immediately
scanned using a GenePix 4000B fluorescence scanner (Molecular Devices). The image was
analyzed using GenePix Pro software (Axon Instruments) and the raw data was analyzed
based on the signal-to-noise ratio and reproducibility. For each feature a CompositeZ score
was calculated as described previously (29, 30). The refined data was visualized using
Spotfire software (Spotfire TIBCO Software). Assay positives with a CompositeZ score ≥3
were compared to the control screen and all other SMM screens within Chembank database
to filter nonspecific binders.
Reporter assay
The MMP1 promoter region (1537 bases upstream of the start codon) was amplified from
genomic DNA (5’: CTAGCGCAAACCTGATACAGTGGGAAAGGTGG and 3’:
ATCTCGAGCAGTGCAAGGTAAGTGATGGCTTCC) and cloned in pGL3 vector
(Promega). The tyrosinase promoter region (712 bases upstream of the start codon) was
amplified from genomic DNA (5’: CTAGCGCTCTTTAACGTGAGATATCCCCACAATG
and 3’: ATCTCGAGCTTCCTCTAGTCCTCACAAGGTCTGCAGG). 501mel cells were
seeded in 6 cm Petri dishes and co-transfected with Renilla plasmid (Promega), reporter
construct in the presence or absence of ETV1 plasmid. The ratio of reporter to driver was
2:1. After 24 hours the cells were reseeded in triplicate 96 well plates (~5000 cells/well) and
incubated for 24 hours in the presence of 10μM BRD32048. The luciferase signal was
measured using a dual-luciferase reporter assay (Promega) according to manufacturer's
protocol. The luminescence signal was read using a Luminoskan Ascent instrument (Thermo
Electron).
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Protein purification
A codon-optimized sequence of full length ETV1 was cloned into a pcDNA3.4 vector
(Invitrogen). Synthesized ETV1 sequence included at C-terminus a FLAG tag sequence and
a streptavidin binding peptide sequence (SBP tag). The vector was transfected into
HEK293F (Invitrogene) cells adapted to grow in suspension to enable the up scaling of
protein production. After 72 hours the cells were harvested and lysed in 1xRIPA buffer
supplemented with 2× complete protease inhibitors (Roche). The lysates were cleared by
centrifugation at 15,000 rpm for 20 min at 4°C and filtered trough a 0.2 μm filter. The ETV1
protein was bound to a streptavidin column via SBP tag and eluted in 2 mM biotin in PBS
buffer.
Surface plasmon resonance experiments
The surface plasmon resonance assays were conducted on a Biacore T200 instrument using
Biacore CM5 sensor chips (Biacore). Ethanolamine, N-ethyl-N’-(3-dimethylaminopropyl)
carbodiimide (EDC), N-hydroxysuccinimide (NHS) and P-20 surfactant were all obtained
from GE Lifesciences. M2 Flag antibody was obtained from Sigma. Reference proteins were
obtained from Origene.
Sensor chip preparation—The surface of the sensor chip was conditioned using
alternating 1-minute injections (30 μL/min flow rate) of 10 mM glycine pH 2.2 and 50 mM
NaOH (repeated 3 times). Surface carboxyl groups were activated with 1:1 0.4M EDC/0.1M
NHS. A 30 μg/mL solution of anti-FLAG in acetate buffer pH 4.5 was flowed for 10
minutes at a rate of 5 μL/min over all four flow cells. The remaining NHS-ester groups on
the sensor surface were quenched with a 7-minute injection of 1 M ethanolamine.
Recombinant ETV1-FLAG and FLAG-tagged proteins were diluted to 5 μg/mL and
captured on the anti-FLAG antibody surface with a 10 to 30 minutes injection at 5 μL/min.
Between 1700 and 2300 response units (RU) of protein were captured for each assay. The
running buffer used during immobilization and capture was HBS, pH 7.4 with 0.05% P-20
surfactant.
Assay parameters—Small-molecule binding assays were performed at 25 °C. The
running buffer for the binding assays was HBS, pH 7.4 supplemented with 0.05% P-20
surfactant and 2% DMSO as a cosolvent. Compounds were diluted from 10 mM DMSO
stocks in the appropriate concentrations in buffer with the same solvent concentration as the
running buffer (2% DMSO). Binding was measured for a range of concentrations (from 0.78
μM to 50 μM) injected in duplicate. Compound solutions were injected for 60 seconds at a
flow rate of 60 μl/min followed by 120 seconds of buffer only.
Data Analysis—Sensorgram data, the equilibrium plot and the residual plot were analyzed
using BiaEvaluation software (GE LifeSciences). Data was reference-subtracted and
corrected for variations in solvent concentration. Binding affinity was calculated using
kinetic and steady state analyses. Kinetic analysis was performed using a least-squares fit of
a Langmuir 1:1 binding model with locally measured Rmax values. The timing for
association phase is adjusted at 2 seconds after the start of injection and 3 seconds before the
end of injection. The steady state affinity constant for each ligand was derived from a plot of
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Req against concentration. The plot was then fitted to a general steady state model. The
graphs displaying the binding level to various surfaces (see supplementary figures 2bcd and
3bc) were created using the BiaEvaluation software where the cycle number (X axis)
represents the number of injections of buffer or compound solutions.
Gene expression signatures
LNCaP cells were seeded in 6 well plates and induced with 100 ng/mL doxycycline for 4
days. LNCaP shRNA sequences: shETV1-872= GCATCTCCAAACTCAACTCAT and
shETV1-1117= CGACCCAGTGTATGAACACAA. SK-MEL-28 cells were infected with
lentivirus encoding two different ETV1 shRNAs
(shETV1-3=GACCCAGTGTATGAACACAA and
shETV1-5=GAGAGAGATATGTCTACAAGTTT) or sh-GFP for 24 hours followed by 3
days puromycin selection. Both cell lines were treated with 20 μM BRD32048 for 16 hours.
Each condition was performed in triplicate. Total RNA was collected using QIAgen RNA
extraction kit. mRNA expression data was obtained using Affymetrix HT Human Genome
U133A arrays according to the manufacturer's instructions. Gene-centric expression values
were obtained using updated Affymetrix probe set definition files (CDF files) based on
Entrez Gene (hthgu133ahsentrezg) from Brainarray version 15, which consists in 12,012
unique genes (31). Background correction was accomplished using RMA (Robust Multichip
Average) (32) and quantile normalization (33). For each experimental condition, we fitted a
linear model using Linear Models for Microarray Data (LIMMA) (34) and calculated the
average fold-change for each gene between that experimental condition and the control.
Gene expression signatures were built using a fold-change cutoff of 1.5 and an FDR-
adjusted q-value ≤ 0.25. p-values for the significance of the signatures’ overlap were
calculated using Fisher's exact test taking into account the total number of genes measured
(12,012). The microarray data (raw data, normalized data and metadata file) are deposited in
GEO (accession# GSE52154).
Invasion and proliferation assays
Cancer cell lines LNCaP, PC3 and SK-MEL-28 were purchased from ATCC. 501mel and
primary melanocytes were purchased from Cell Culture Core Facility, Yale University, New
Haven, Connecticut. These cell lines were not authenticated in our laboratory. For invasion
assays, cells were serum-starved for 24 hours prior to conducting invasion assays as
described previously (35). Briefly, 250,000 cells/well were seeded in Millipore collagen
trans-well plates and each condition was carried out in quadruplicates. The relative amounts
of invading cells were measured calorimetrically according to the manufacturer protocol
using a SpectraMAX 190 instrument (Molecular Devices). Final values were corrected for
background signal (empty well). Proliferation assay was performed in 96 well plates where
cells were seeded at 3000 cells/well followed by compound treatment for 4 days. The
relative number of cells was quantified using a CellTiter-Glo assay (Promega).
Biotin-oligonucleotide precipitation
Cells expressing Flag-HA-tagged ETV1 were lysed in 1x RIPA buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% Sodium deoxycholate, complete
protease inhibitors) and diluted 1:10 in EMSA buffer (Pierce) to a final volume of 1 mL.
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Unlabeled or Biotin-labeled oligonucleotides (wt - 5’: Biotin-
TCTACCAAGACAGGAAGCACTTCCTGGAGATTAATC and scrambled – 5’:
AGTCGTCATGCATTAAGCTGTTGTTGAAGAGTGTAC) were added at 5 pmol/
reaction. The compound was added during the pull-down reaction at the stated
concentrations. The complexes were precipitated for 2 hours at 4°C using streptavidin
magnetic beads (Pierce) and washed 3 times with EMSA buffer. The samples were
subjected to western blotting and probed with anti-HA antibody (Covance).
Immunoprecipitations and western blotting
Cells were lysed in cold lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% (v/v) NP-40,
0.5% (v/v) Triton-100, 5 mM MgCl2, 1 mM EDTA, 1× complete protease inhibitors). 3 mg
total protein was subjected to immuno-precipitation using anti-HA agarose beads (Covance)
or anti-FLAG M2 agarose beads (Sigma). Samples were washed 3 times in lysis buffer,
boiled in 1× sample buffer and resolved by SDS PAGE. p300 silencing was performed using
p300 short hairpin (Santa Cruz) delivered by lentiviral infection. Antibodies used: p300
(N-15, Santa Cruz); P/CAF (C14G9), anti K-acetyl (Cell Signaling); ETV1 (ab81086,
Abcam); vinculine, actin, FLAG (F7425) (Sigma); V5 (Invitrogen).
RESULTS
Identification and validation of BRD32048 as direct binder of ETV1
To identify small molecules that interact with ETV1, we pursued an SMM screening
approach using methods described previously (25, 26, 36). We used cell lysates instead of
purified ETV1 protein for the SMM screens to allow it to undergo additional regulation that
might be relevant to the mammalian cellular environment. Like other ETS factors, the ETV1
protein conformation is thought to be regulated by various post-translational modifications
and protein-protein interactions, several of which may be altered during the purification
process (25, 26). We generated cell lysates from HEK 293T cells transiently transfected with
a HA-tagged ETV1 expression vector (Supplementary Fig. S1a), resulting in moderate
ETV1 expression levels (Supplementary Fig. S1a). A total of 45,000 compounds were
screened against HA-ETV1-expressing lysates in triplicate. To identify “hits” from this
screen, we calculated a composite Z score for each compound as published previously (37).
Analysis of the composite Z-scores corresponding to the primary SMM screen revealed six
assay positives (fig. 1a and Supplementary Fig. S1b) that showed selectivity toward ETV1
relative to >100 additional proteins, including other transcription factors, that had previously
been screened using the same SMM library (24, 29).
Next, we sought to determine whether the candidate small-molecule binders identified in the
SMM screen might alter ETV1 activity in an endogenous cellular context. As a preliminary
means to test this, we evaluated the top six compounds that emerged from the screen (based
on a composite Z score; see methods) in a cell-based reporter construct where the MMP1
promoter was cloned upstream of the luciferase gene (MMP1 is a known ETV1 target gene
(17)). We consistently observed that compound 1, hereafter termed BRD32048, was able to
suppress luciferase activity by ~50% in 501mel melanoma cells, which harbor an ETV1
amplification (fig. 1b). To confirm that this molecule did not interfere with the general
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transcriptional machinery, we also tested its effects in a reporter assay with the tyrosinase
(TYRP1) promoter, which is activated downstream of the microphthalmia-induced
transcription factor (MITF) (38). MITF is a known melanoma oncoprotein (39) that is
structurally unrelated to ETS transcription factors. In this context, BRD32048 had no effect
on the luciferase signal, suggesting that the compound effects were not solely due to
nonspecific transcriptional or post-transcriptional modulation (Supplementary Fig. S1c).
BRD32048 is a substituted [1,3,5]triazine derivative. This synthetic scaffold has previously
been observed in orally active PDE inhibitors (40), DHFR inhibitors (41), and PI3K/mTOR
inhibitors (42, 43), among others. As an additional control to rule out nonspecific compound
effects, we tested a small set of commercially available BRD32048 analogs that contain the
[1,3,5]triazine core but vary either the methoxyphenyl group in the 4-position or the alkyl
piperidine group in the 6-position. Using the MMP1 reporter assay in the LNCaP prostate
cancer cell line, we observed that major substitutions negatively impacted the inhibitory
effect of the triazine scaffold in this reporter assay, whereas minor substitutions failed to
enhance its inhibitory activity (Supplementary Fig. S1d). Therefore we resynthesized
BRD32048 and used this compound for all subsequent experiments (the chemical
characterization is presented in supplementary material and methods).
We next sought to determine whether BRD32048 binds ETV1 directly. Here, we used a
surface plasmon resonance (SPR) approach, in which the SPR surface was configured using
anti-FLAG M2 antibody to capture FLAG-tagged proteins. The M2 antibody was covalently
immobilized to a carboxymethyl dextran surface. Recombinant ETV1 was purified from
HEK293F cells (Supplementary Fig. S2a) and captured onto the antibody surface resulting
in a stable baseline (Supplementary Fig. S2b). Next, BRD32048 was injected at increasing
concentrations from 0.78 μM up to 50 μM (fig. 1c; see Methods). For the reference surface
we used TBX21, an unrelated transcription factor with a comparable molecular weight (55
kDa) and isoelectric point (~5.8). The reference surface showed no specific interactions,
whereas the ETV1 surface recorded an increasing response in a concentration dependent
manner (Supplementary Fig. S2c,d).
Kinetic binding analysis of BRD32048 to ETV1 was carried out using a simple 1:1
Langmuir model, which provided a KD of 17.1 μM. The residual plot revealed that the noise
level did not exceed 0.4 RU. Moreover, the steady state equilibrium analysis of the same
experiment with TBX21 reference provided a similar KD of 23.2 μM (fig. 1c). In addition,
the kinetic analysis and steady state equilibrium analysis using anti-FLAG M2 antibody as
reference revealed similar binding affinity for ETV1 (Supplementary Fig. S3a,b). We also
evaluated binding of BRD32048 to other protein-coated sensor surfaces including RELA,
RUNX1, RFWD2 and P/CAF without observing any specific binding (Supplementary Fig.
S3c). Moreover, the fact that BRD32048 did not bind to low isoelectric point surfaces (such
as TBX21 and RELA) suggests that binding to ETV1 was not merely the result of unspecific
charge-based interactions. Together, these results suggested that BRD32048 is capable of
binding ETV1 directly.
To confirm that BRD32048 is able to bind ETV1 in lysates, we performed a compound pull-
down experiment in which BRD32048 was covalently attached to beads. The coupling was
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carried out using an isocyanate chemistry-based approach similar to that used in SMM (see
supplementary methods). Incubation of 501mel cells lysates with BRD32048-beads showed
that BRD32048 was able to precipitate endogenous ETV1, whereas addition of excess
amounts of soluble BRD32048 was able to significantly out compete the immobilized
compound from binding to ETV1 (Supplementary Fig. S3d). These data provided further
evidence that BRD32048 is capable of binding ETV1 in cells.
BRD32048 modulates an ETV1 transcriptional signature
Although the reporter-based experiments raised the possibility that BRD32048 might
perturb ETV1 activity in cells, these assays rely on an artificial read-out that is not
necessarily specific to ETV1 function. To ascertain whether BRD32048 might modulate
endogenous ETV1 function, we examined its effects on an empirically determined
transcriptional signature linked to ETV1 activity. To generate this ETV1 signature, we used
derivatives of the LNCaP prostate cancer cell line engineered to express two distinct
inducible shRNAs against ETV1 (shETV1-1117 and shETV1-872). LNCaP cells are known
to harbor a chromosomal rearrangement that translocates the entire ETV1 locus in an
androgen-regulated region (8, 9). Induction with doxycycline for 4 days caused a marked
reduction of ETV1 mRNA levels (fig. 2a), which was also confirmed by quantitative RT-
PCR (Supplementary Fig. S4a). The ETV1 protein is virtually eliminated after 4 days of
silencing as shown in nuclear extracts (Supplementary Fig. S4b). The proliferation of
LNCaP cells also appears to be ETV1 dependent, although the reduction in proliferation
only became apparent at later time points (Supplementary Fig. S4c). Using this system, we
defined a gene expression signature linked to ETV1 activity by calculating the fold change
in expression levels for each gene measured. The final list of differentially expressed genes
consist of either up-regulated or down-regulated genes with a fold change of >1.5.
To derive a gene expression signature linked to BRD32048 exposure, parental LNCaP cells
were treated with 20 μM BRD32048 for 16 hours. Using the same analysis approach (see
methods), we identified genes with a fold change greater than 1.5 following BRD32048
exposure, and a false discovery rate of < 0.25. We then determined the overlap between the
ETV1 shRNA signature and the BRD32048 signature by intersecting the lists of
differentially up- and down-regulated genes. Strikingly, ~51-58% of up-regulated and
~76-91% of down-regulated genes following BRD32048 exposure were also up- or down-
regulated following shRNA-mediated knockdown of ETV1. This degree of overlap was
highly significant for both up-regulated (p = 4.0 × 10−20 and p = 4.9 × 10−25 for the two
shRNA signatures) and down-regulated (p = 8.9 × 10−34 and p= 2.8 × 10−138) genes (fig.
2b,c). The overlap remained highly significant (up-regulated p = 5.4 × 10−13 and down-
regulated p = 2 × 10−39) when the two shETV1 signatures were merged and intersected with
both compound signatures (Supplementary Fig. S4d), suggesting that BRD32048 may
modulate the ETV1-dependent signature. From the down-regulated genes common to these
four sets we selected 8 genes that harbor multiple potential ETS binding sites in their
promoter region and tested their expression following shETV1 or BRD32048 treatment.
Quantitative RT-PCR results confirmed the microarray data, indicating comparable
reductions in expression levels (Supplemental Fig. S4e). In contrast, similar experiments
performed in the SK-MEL-28 melanoma cell line did not yield any overlap between
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signatures obtained following shRNA knockdown of ETV1 (shETV1-3 and shETV1-5) and
exposure of the cells to BRD32048 (fig. 2d,e). ETV1 knockdown was confirmed by
quantitative RT-PCR and western blot (Supplementary Fig. S4a,b). These results suggests
that the effects of this compound may be influenced by genetic or lineage factors.
BRD32048 inhibits invasion of ETV1-dependent cell lines
We next wished to determine whether BRD32048 might modulate a tumor cell phenotype
that is governed by ETV1 activity. Toward this end, ETV1 silencing can inhibit invasion or
survival of some ETV1-dependent cancer cell lines (10, 44). We generated an isogenic
system where primary melanocytes expressing NRASG12D were infected with either ETV1
or MYC (Supplementary Fig. S5a). These cell lines were assessed using an established
collagen-based invasion assay (35). Ectopic expression of ETV1 in primary melanocytes
expressing constitutive active NRASG12D significantly stimulates the invasive potential of
these cells (Supplementary Fig. S5b). Treatment with BRD32048 for 24 hours inhibited
invasion of cells expressing ETV1 in a dose-dependent manner, but not those expressing
MYC (fig. 3a). In contrast, we observed no inhibitory effects on the invasive phenotype of
primary melanocytes expressing mutant NRAS only (Supplementary Fig. S5c), suggesting
that the inhibitory effects involve an ETV1 cellular context. LNCaP cells were inhibited in a
concentration-dependent manner, with the highest concentration yielding comparable
potency as with ETV1 knockdown (fig. 3b). These results are reminiscent of prior studies
showing that the invasive phenotype of LNCaP cells can be suppressed by silencing of
ETV1 (44). In contrast, the invasion phenotype of PC3 cell line (which lack ETS factor
rearrangements) was insensitive to compound treatment, likely because the invasive
phenotype of PC3 cell line does not appear to be dependent on ETV1 (Supplementary Fig.
S5d). Interestingly, 501mel cells, which have been shown previously to be ETV1-dependent
(10) also showed suppressed invasive capacity following BRD32048 exposure, whereas SK-
MEL-28 cells were unaffected (Supplementary Fig. S5e). The lack of effect of BRD32048
on SK-MEL-28 invasion is consistent with the observation that BRD32048 also did not
inhibit the ETV1 signature in this cell line. The inhibitory effects of BRD32048 on the
invasion phenotype of sensitive cell lines did not result from a global impairment of cell
viability, since the cell lines used in the invasion assay showed no diminution of
proliferative potential over 4 days in the presence of 20, 50 and 100 μM BRD32048
compared to untreated controls (Supplementary Fig. S5f). Collectively, these results suggest
that BRD32048 may inhibit a tumorigenic phenotype linked to ETV1 function.
BRD32048 inhibits ETV1 acetylation and promotes its degradation
To begin to explore the mechanism by which BRD32048 might perturb ETV1, we sought to
determine its effect on ETV1 protein function. We first assessed DNA-binding capacity (45)
in the absence or presence of BRD32048 by performing oligonucleotide pull-down assays.
Here, biotin-labeled oligonucleotides containing ETS binding sites were used to precipitate
ETV1 from lysates of HEK 293T or LNCaP cells that overexpressed Flag-HA-tagged
ETV1. BRD32048 had no effect on ETV1 pull-down in this assay, even at 100 μM
concentrations (Supplementary Fig. S6a). In contrast, ETV1 pull-down was largely
abrogated by excess unlabeled oligonucleotide, suggesting that the oligo-bound ETV1 may
represent a relatively specific interaction. These results implied that BRD32048 might
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perturb ETV1 function in a DNA binding-independent manner, although a possible role for
off-target compound effects could not be excluded completely.
We next sought to ascertain whether BRD32048 might alter the stability of ETV1 protein.
To test this, we performed time course experiments to monitor the effects of the compound
on exogenous Flag-HA ETV1 protein levels in the absence or presence of BRD32048. In the
presence of cycloheximide (CHX), which blocks protein synthesis, the half-life of ETV1
was markedly reduced following pre-treatment of either LNCaP or 501mel cells with
BRD32048 for 24 hours. In contrast, BRD32048 did not affect ETV1 stability in SK-
MEL-28 cells; this observation accords with the lack of BRD32048 effect on either the
ETV1 gene expression signature or the invasion phenotype in these cells (fig. 4a). The
BRD32048-induced instability of exogenous ETV1 is also valid for endogenous ETV1 in
501mel and LNCaP cells following overnight treatment with BRD32048 (Supplementary
Fig. S6b). This result suggested that BRD32048 might promote degradation of ETV1 in
some but not all cellular contexts.
Previous studies suggest that ETV1 stability is enabled through acetylation of lysines
situated at residues 33 and 116 (46). To determine if BRD32048 might alter ETV1
acetylation, we expressed Flag-HA-tagged ETV1 in our cell line panel, performed
immunoprecipitations of ETV1 using an anti-Flag antibody, and examined its acetylation
status by immunoblotting. ETV1 acetylation was readily detected following anti-Flag
immunoprecipitation in LNCaP and 501mel cells (fig. 4b). In contrast, no acetylation was
observed in PC-3 cells or SK-MEL-28 cells, even after over expression of exogenous p300
(Supplementary Fig. S6c). Interestingly, the ETV1 acetylation status was substantially
reduced in both LNCaP and 501mel cells following 24 hours of pre-treatment with 50 μM
BRD32048, which was consistent with the reduction in ETV1 stability induced by this
compound (fig. 4b). Together, these results raised the possibility that BRD32048 binds and
inhibits ETV1 function by reducing its acetylation and stability, thereby promoting cell
context-dependent protein degradation.
Since various acetyltransferases are known to acetylate ETV1 (46), we sought to determine
if the loss of acetylation conferred by BRD32048 in certain cell contexts might be linked to
the activity of a particular histone acetyltransferase (HAT) protein. To test this, we co-
expressed ETV1 together with either p300 or P/CAF in HEK293T cells in the absence or
presence of 50 μM BRD32048. In this cell system, ectopic expression of both p300 and
P/CAF induced ETV1 acetylation, as measured by Flag-immunoprecipitation followed by
immunoblotting with the anti-acetyl antibody (fig. 4c). However, only p300-dependent
acetylation was inhibited by BRD32048 in this setting (fig. 4c). In addition, shRNA-
mediated knockdown of p300 protein reduced ETV1 protein levels in LNCaP and 501mel
cells (fig. 4d).
Previous studies have shown that p300 acetylates ETV1 at residues K33 and K116, and that
these residues may also regulate ETV1 protein stability (46). Therefore, we reasoned that
overexpression of an acetylation-deficient ETV1 mutant might counteract the inhibitory
effects of BRD32048 towards this protein. We therefore generated a mutant form of ETV1
(K33R/K116R), which can no longer be acetylated by p300 (46) (Supplementary Fig. S6d).
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Addition of BRD32048 to ETV1(K33R/K116R) expressing cells had no effect on invasion
(Supplementary Fig. S6e,f), in contrast to the effects of BRD32048 in cells overexpressing
wild type ETV1. Collectively, these findings suggest that BRD32048 may reduce p300-
dependent ETV1 acetylation, thereby decreasing its stability in a context-dependent manner.
DISSCUSION
Although many transcription factors play important roles in carcinogenesis and tumor
progression, this class of proteins is traditionally considered poorly “druggable” by
conventional means. Our results suggest that SMM screening may provide one approach
through which to discover chemical probes that modulate the function of these and perhaps
other “undruggable” proteins. Although we interrogated only 45,000 printed compounds, the
SMM platform could easily be scaled to accommodate 100,000s of compounds in the future.
For our SMM screens, we utilized cell lysates that contained epitope-tagged ETV1. This
approach may offer several advantages compared to the use of purified protein, as described
previously (47). First, the use of cell lysates allows the protein of interest to be expressed in
an appropriate cell context; e.g., mammalian cells instead of bacterial or insect cells. This
may allow the protein to undergo physiologically relevant post-translational modifications
that may affect its three dimensional structure and therefore its available binding surface.
Second, lysates may retain multiprotein complexes that affect the conformation or avidity of
the query protein. Third, preparation of cell lysates may offer technical advantages over
protein purification, which may require extensive optimization to preserve protein folding
and activity. Despite these potential advantages, it is often still necessary to utilize purified
protein for subsequent validation steps, such as surface plasmon resonance (SPR) based
binding studies, as performed here. Also, the use of lysates may carry an increased risk of
false positives during the primary screen because of binding to other members of
multiprotein complexes or nonspecific interacting proteins. In the future, multiple SMM
screens could be conducted in parallel using various alternative lysate preparations; e.g., by
expressing distinct epitope-tagged proteins in several cellular contexts prior to harvest. Here,
small molecule “hits” identified in multiple screens could be prioritized for validation. The
use of nuclear extracts instead of total protein lysates may also offer advantages in SMM
screens that interrogate transcription factors.
Several lines of evidence support the premise that BRD32048 may alter the cellular function
of ETV1 through direct binding. First, the SPR analysis indicates that BRD32048 can bind
purified ETV1, albeit at micromolar concentrations. In addition, a BRD32048 affinity resin
is capable of precipitating endogenous ETV1 from cell lysates. Second, BRD32048
modulates a gene expression signature linked to ETV1 activity in cancer cell lines known to
harbor an ETV1 dependency. The gene expression signature is directly linked to the
availability and function of ETV1 protein. While BRD32048 only marginally decreased
ETV1 mRNA, it dramatically reduces ETV1 protein levels in certain cellular contexts,
resembling the effects of shETV1. This may explain the overlapping mRNA signature
between these two conditions. Third, BRD32048 exposure results in decreased ETV1
acetylation in the same cancer cell lines in which it modulates the ETV1 signature and
inhibits their invasion. Our data demonstrate that BRD32048 directly modulates the ETV1
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protein stability, leading to a significant decrease in the amount of ETV1 molecules
available to carry out the oncogenic functions of ETV1.
However, the exact location within the ETV1 protein to which BRD32048 binds remains
unclear. One possibility is that the compound blocks K33 since P/CAF-dependent
acetylation remains unaffected. Another possibility is that BRD32048 is directly interfering
with a co-factor interaction or perhaps p300. The investigation of differential binding of
ETV1 to its interaction partners in the presence or absence of BRD32048 may require
structure-activity relationship (SAR) studies to identify derivatives that bind ETV1 with
much higher affinity in vitro. Such studies would certainly aid understanding its specificity
towards other cellular proteins, enabling quantitative target identification experiments
involving mass spectrometry (48), as well as improve its in vivo potency. In the future, these
avenues will likely be needed to develop molecules such as BRD32048 into mature
chemical probes that explore biological processes and possible therapeutic avenues linked to
oncogenic transcription factors.
The observation that BRD32048 exposure may destabilize ETV1 by reducing its acetylation
may highlight an alternative approach to therapeutic modulation of certain transcription
factors that involves blocking vital post-translational modifications. In contrast to the
transcription factors themselves, protein acetyltransferases may prove amenable to more
conventional small-molecule discovery approaches. Toward this end, histone
acetyltransferases (HATs) are well-known transcriptional co-activators, and several histone
acetyltransferase inhibitor tool compounds have been developed (49). Moreover, several
previous reports have found that multiple ETS transcription factors including ETV1 can be
regulated by acetylation in general and by p300 HAT activity in particular (46, 50). Thus
far, however, few HAT inhibitors have entered clinical development. Additional studies of
HAT inhibitors that exhibit selectivity for p300 may provide additional insights into the
possible efficacy of such approaches against cancer cells that show dependence on ETV1 or
other ETS factors for viability or tumor progression.
In summary, this study employed a small molecule microarray (SMM) screen to identify a
compound capable of binding and inhibiting ETV1. The results may endorse a general
approach to the discovery of chemical probes that modulate transcription factors and other
currently “undruggable” oncoproteins. Such studies may pave the way for future systematic
efforts with important implications for chemical biology and therapeutic discovery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of BRD-K77432048 as a direct ETV1 binder
(a) Structures for six SMM assay positives are shown (see text for details). (b) 501mel cells
were co-transfected with ETV1- or MMP1-driven firefly luciferase and treated with 10μM
BRD32048 or DMSO for 24 hours. The fold induction of Firefly signals were normalized to
Renilla luciferase and divided by the reporter only/DMSO control. (c) HEK293F-purified
ETV1-FLAG and TBX21-FLAG were captured onto M2 αFlag antibody surface for SPR
studies (see text). Compound solution was injected at increasing concentrations from 0.78
μM to 50 μM. Response units (RU) are corrected for solvent variations and referenced to
TBX21 surface. The sensorgram was fitted using a 1:1 Langmuir model and the steady state
equilibrium uses the RU values at 5 seconds before the end of compound injections.
Included is the kinetics residual plot as well as the statistical kinetic parameters values for
Ka, Kd and Chi2.
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Figure 2. Comparisons between ETV1 and BRD32048 gene expression signatures
(a) ETV1 mRNA levels in LNCaP.sh1117 and LNCaP.sh872 cells treated with Doxycycline
(ETV1 shRNAs), DMSO or BRD32048. shETV1 induced signature and 20 μM BRD32048
induced signature generated in LNCaP.sh1117 (b) and LNCaP.sh872 (c) are intersected for
the up-regulated genes and down-regulated genes. (d) ETV1 mRNA levels in SK-MEL-28
cells expressing shGFP, shETV1-3 or shETV1-5 and treated with DMSO or BRD32048. (e)
The combined signature induced by shETV1-3 and shETV1-5 was intersected with the 20
μM BRD32048-induced signature for the up-regulated genes and down-regulated genes. The
p-value (see methods) for each comparison is included.
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Figure 3. Effects of BRD2048 on tumor cell invasion
(a) Invasion of primary melanocytes, co-expressing NRASG12D with either ETV1 or MYC,
was measured in invasion chambers after 24 hours in the presence of DMSO or BRD32048
at the indicated concentrations. (b) Invasion of LNCaP(shETV1-872) and PC3 cells was
measured as indicated above. LNCaP cells were also treated with doxycycline for 4 days to
express the shETV1-872.
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Figure 4. Effects of BRD2048 on ETV1 stability and acetylation
(a) LNCaP and 501mel cells expressing Flag-HA-ETV1 and SK-MEL-28 expressing V5-
ETV1 were pretreated (16 hours) with BRD32048 (50 μM) and subjected to a
cycloheximide (100 μM) time course. ETV1 levels were evaluated at the indicated time
points by immunoblotting. The proteasome inhibitor MG132 (10μM) was used as a control.
Actin and Vinculin were blotted for loading control. (b) LNCaP, PC3 and 501mel cells
expressing FLAG-HA-ETV1 or SK-MEL-28 expressing V5-ETV1 were pretreated (16
hours) with 50 μM of BRD32048. ETV1 immunoprecipitations were performed, and the
resulting protein was probed with an antibody recognizing acetylated lysine (αK-Ac).
Vinculin was probed as loading control. (c) HEK293T cells co-expressing Flag-HA-ETV1
and either p300 or P/CAF were pretreated (16 hours) with 50 μM of BRD32048.
Precipitated ETV1 was probed with anti Lysine-acetyl antibody. (d) LNCaP and 501mel
cells were infected with lentivirus expressing a p300 or luciferase shRNA (72 hours).
Thereafter the cells were transfected with Flag-HA-ETV1. After 48 hours, immunoblots
were performed using antibodies directed against p300, HA-tag, or vinculin (control).
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